Table 2 Comparison of the TRACP-5b/iPTH ratio among the three categories (low, medium, and high)
TRACP-5b/iPTH ratio | P value | |||
|---|---|---|---|---|
Low (Quartile 1) | Medium (Quartile 2) | High (Quartile 3) | ||
< 2.06 | ≧2.06, < 4.46 | 4.46≦ | ||
N | 36 | 35 | 35 | – |
Age, years | 65 [54, 72] | 68 [63, 75] | 69 [64, 76] | 0.010 |
Female sex, n | 13 | 15 | 17 | 0.568 |
BMI, kg/m2 | 21.9 [20.6, 24.6] | 23.0 [20.1, 27.1] | 20.1 [18.4, 21.8] | 0.003 |
Chronic HD vintage, years | 6.8 [3.6, 13.5] | 8.7 [3.0, 12.3] | 8.0 [2.5, 12.0] | 0.730 |
Anticoagulant during HD, n (%) | ||||
 Heparin | 30 (83.3) | 31 (88.6) | 29 (82.9) | 0.299 |
 LMWH | 4 (11.1) | 4 (11.4) | 2 (5.7) | |
 Nafamostat | 2 (5.6) | 0 (0) | 4 (11.4) | |
Cause of ESRD, n | ||||
 Diabetic nephropathy | 12 | 9 | 13 | 0.840 |
 Nephrosclerosis | 9 | 9 | 7 | |
 Glomerulonephritis | 10 | 11 | 7 | |
 Others | 5 | 6 | 8 | |
Diabetes, n | 15 | 10 | 13 | 0.506 |
Ischemic heart disease, n | 10 | 9 | 8 | 0.892 |
Cerebrovascular disease, n | 9 | 4 | 5 | 0.274 |
CaSR agonist use, n (%) | 26 (72.2) | 22 (62.9) | 13 (37.1) | 0.008 |
 None | 10 (27.8) | 13 (37.1) | 22 (62.9) | 0.001 |
 Cinacalcet/ Evocalcet | 20 (55.6) | 22 (62.9) | 13 (37.1) | |
 Etelcalcetide (i.v.) | 6 (16.7) | 0 (0) | 0 (0) | |
VDRA use, n (%) | 35 (97.2) | 34 (97.1) | 28 (80.0) | 0.012 |
 None | 1 (2.8) | 1 (2.9) | 7 (20.0) | 0.001 |
 Alfacalcidol/ Falecalcitriol | 10 (27.8) | 18 (51.4) | 20 (57.1) | |
 Calcitriol (i.v.) | 14 (38.9) | 13 (37.1) | 5 (14.3) | |
 Maxacalcitol (i.v.) | 11 (30.6) | 3 (8.6) | 3 (8.6) | |
P binder use, n (%) | 30 (83.3) | 31 (88.6) | 29 (82.9) | 0.759 |
 None | 6 (16.7) | 4 (11.4) | 6 (17.1) | 0.471 |
 Ca containing | 3 (8.3) | 3 (8.6) | 6 (17.1) | |
 Non-Ca containing | 20 (55.6) | 22 (62.9) | 13 (37.1) | |
 Both | 7 (19.4) | 6 (17.1) | 10 (28.6) | |
Steroid use history, n (%) | 5 (13.9) | 4 (11.4) | 4 (11.4) | 0.935 |
β blocker use, n (%) | 18 (50.0) | 18 (51.4) | 12 (34.3) | 0.277 |
Statin use, n (%) | 12 (33.3) | 7 (20.0) | 9 (25.7) | 0.441 |
Warfarin use, n (%) | 0 (0) | 4 (11.4) | 3 (8.6) | 0.130 |
Bisphosphonate use, n (%) | 5 (13.9) | 4 (11.4) | 5 (14.3) | 0.929 |
Fracture history, n | 3 | 6 | 6 | 0.468 |
Ankle-brachial index | 1.10 [1.03, 1.18] | 1.09 [1.03, 1.18] | 1.10 [1.01, 1.17] | 0.819 |
Alb, g/dL | 3.6 [3.3, 3.8] | 3.6 [3.4, 3.8] | 3.6 [3.4, 3.7] | 0.628 |
cCa, mg/dL | 8.9 [8.4, 9.3] | 9.2 [8.6, 9.6] | 9.1 [8.7, 9.5] | 0.109 |
P, mg/dL | 5.6 [4.7, 6.4] | 5.3 [4.5, 6.0] | 5.0 [4.3, 5.6] | 0.054 |
iPTH, pg/mL | 300.1 [227.9, 441.2] | 196.7 [129.3, 269.2] | 118.8 [66.8, 187.8] | 0.0001 |
25(OH)D, ng/mL | 14.0 [11.6, 18.0] | 16.6 [12.3, 20.3] | 13.3 [9.7, 17.3] | 0.075 |
1, 25(OH)2D, pg/mL | 10.0 [5.0, 14.5] | 15.0 [11.0, 22.0] | 16.0 [8.0, 21.0] | 0.003 |
BAP, μg/L | 12.7 [9.3, 18.2] | 14.3 [10.8, 18.3] | 15.0 [11.3, 19.4] | 0.343 |
TRACP-5b, mU/dL | 347.5 [239.5, 500.5] | 591.0 [339.0, 777.0] | 848.0 [567.0, 1060.0] | 0.0001 |